De novo chromosome 7q36.1q36.2 triplication in a child with developmental delay, growth failure, distinctive facial features, and multiple congenital anomalies: a case report
- 1.2k Downloads
Studying human genome using chromosomal microarrays has significantly improved the accuracy and yield of diagnosing genomic disorders. Chromosome 7q36 deletions and duplications are rare genomic disorders that have been reported in a limited number of children with developmental delay, growth retardation, and congenital malformation. Altered dosage of SHH and HLXB9, both located in 7q36.3, is believed to play roles in the phenotypes associated with these rearrangements. In this report we describe a child with 7q36.1q36.2 triplication that is proximal to the 7q36.3 region. In addition to the clinical description, we discuss the genes located in the triplicated region.
We report a 22 month old male child with a de novo 1.35 Mb triplication at 7q36.1q36.2. His prenatal course was complicated by oligohydramnios, intrauterine growth restriction, and decreased fetal movement. Hypotonia, respiratory distress, and feeding difficulty were observed in the neonatal period. He also had developmental delay, cardiovascular malformation, growth failure with microcephaly, short stature, and underweight, sensorineural hearing loss, myopia, astigmatism, cryptorchidism, hypospadias, microphallus, lower extremity length discrepancy, bifid uvula, single palmer creases, and distinctive facial features including straight eyebrows, ptosis, up-slanted palpebral fissures, broad nasal bridge, low-set and posteriorly rotated ears, small mouth with thick lower lip, microretrognathia, and high-arched palate.
The child presented here had developmental delay, distinctive facial features, multiple congenital anomalies, and 7q36.1q36.2 triplication. This triplication, which was found to be de novo, has not been previously described and is believed to result in the observed phenotype. The triplicated region harbors the GALNTL5, GALNT11, KMT2C, XRCC2, and ACTR3B genes. GALNT11 encodes a membrane-bound polypeptide N-acetylgalactosaminyltransferase that can O-glycosylate NOTCH1 leading to the activation of the Notch signaling pathway. Therefore, increased GALNT11 dosage can potentially alter the Notch signaling pathway explaining the pathogenicity of 7q36 triplication. Studying further cases with similar genomic rearrangements is needed to make final conclusions about the pathogenicity of this triplication.
KeywordsChromosome 7q36 Genomic rearrangements Chromosomal microarray Chromosomal disorders
Studying human genome using chromosomal microarrays has significantly improved the accuracy and yield of diagnosing genomic disorders. Therefore, chromosomal microarrays have been routinely used as a first-tier diagnostic test for individuals with neurodevelopmental disabilities or congenital anomalies . Compared to the 3% diagnostic yield of karyotyping, chromosomal microarray can detect pathogenic copy number variations (CNVs) with a diagnostic yield of 10-20% [2, 3].
Chromosome 7q36 rearrangements are rare genomic disorders. To date, deletions of 7q36 have been described in 47 individuals with developmental delay and growth retardation. Other common features in these individuals are microcephaly, ear malformation, cleft lip and palate, holoprosencephaly, and sacral malformation. Haploinsufficiency of the genes SHH and HLXB9, both located in 7q36.3, are believed to be responsible for the holoprosencephaly and sacral malformation, respectively . Duplications involving the 7q36.3 region have been less frequently reported. Four individuals from a three-generation family were reported with 7q36.3 duplication and intellectual disability, corpus callosum agenesis, Chiari malformation, macrocephaly, and distinctive facial features . Additionally, 7q36.3 duplications were reported in two siblings with muscle hypertrophy and an infant with encephalocele [6, 7]. Although SHH overexpression has been proposed to be responsible for the observed phenotypes in individuals with 7q36.3 duplications, the reason for heterogeneity in the phenotypes remains unclear .
In this report we describe a 7q36.1q36.2 triplication that is proximal to the 7q36.3 region and does not include SHH in a child with developmental delay, growth failure, distinctive facial features, and multiple congenital anomalies.
A 22 months male child born to a second degree cousins who were healthy and had three healthy daughters. He was born at 35 week gestational age via a Cesarean section due to fetal distress. During pregnancy the mother had gestational diabetes that was diet controlled. The prenatal course was complicated by oligohydramnios, intrauterine growth restriction (IUGR), and decreased fetal movement noticed since the beginning of the third trimester. After birth, he was kept in neonatal intensive care unit (NICU) because of low birth weight (1.6 kg) and respiratory distress that required oxygen by nasal cannula for 2 weeks. He also had feeding difficulties required nasogastric tube feeding during the hospitalization. He was discharged home after 6 weeks when his oral feeding and respiratory distress improved.
He also had bilateral cryptorchidism, hypospadias, shallow scrotum, and microphallus. At the age of 3 months the stretched penile length was 1.7 cm. At that age, sonography showed testes in inguinal canals, karyotype showed 46 XY, and hormonal studies showed normal testosterone, luteinizing hormone (LH), thyroid function test, and insulin-like growth factor 1 (IGF-1). He received monthly testosterone injections for 3 months and the stretched penile length increased to 3.8 cm at the age of 6 months. At the age of 1 year he had bilateral orchidopexy.
Bilateral sensorineural hearing loss was diagnosed at the age of 13 months when he had an auditory brainstem response (ABR) testing. Subsequently, he started using hearing aids. In addition, he had snoring and otorhinolaryngology examination showed adenoid hypertrophy. Therefore bilateral myrigotomy and adenoidectomy were performed at the age of 18 months. In addition, he had bilateral congenital ptosis and eye exam at the age of 1 year revealed myopia and astigmatism.
During the NICU stay an echocardiogram showed patent ductus arteriosus with left to right shunt, branch pulmonary artery narrowing, and small aortic arch distal to the brachiocephalic artery and descending aorta. During the first year of life, he had several episodes of respiratory distress that required three hospitalizations and he was diagnosed to have reactive airway disease.
He started talking when he was 20 months and at the time of this report he could say about 10 words. He started rolling over at age of 7 months, sitting unsupported at 8 months, standing holding objects at 18 months, and at the time of this report he was able to walk holding furniture. He could also grasp and move objects from hand to hand, and waive bye-bye. He also had hypotonia since neonatal period. He started receiving speech therapy and physical therapy since the age of 1 year, with which he showed good response with improvements in hypotonia and his motor and language development. Brain MRI was done at the age of 20 months and was normal.
He also had growth failure with all growth parameters below 5th percentiles. He had been eating regular table food and had normal swallowing assessment at the age of 1 year.
Discussion and conclusions
Herein, we describe a 7q36.1q36.2 triplication in a boy with developmental delay, growth failure (microcephaly, short stature, and underweight), cardiovascular malformation (patent ductus arteriosus, branch pulmonary artery narrowing, and small aortic arch and descending aorta), sensorineural hearing loss, eye manifestations (ptosis, myopia, and astigmatism), genital anomalies (cryptorchidism, hypospadias, and microphallus), lower extremity length discrepancy, bifid uvula, single palmer creases, distinctive facial features (straight eyebrows, ptosis, up-slanted palpebral fissures, broad nasal bridge, low-set and posteriorly rotated ears, small mouth with thick lower lip, microretrognathia, and high-arched palate), prenatal complications (oligohydramnios, IUGR, and decreased fetal movement), and hypotonia, respiratory distress, and feeding difficulty observed in the neonatal period.
The 7q36 triplication in this child, which was found to be de novo, has not been previously reported. It is possible that increased dosage of one or more genes in the triplicated region is responsible for the observed phenotype. This region harbors 5 genes: GALNTL5, GALNT11, KMT2C, XRCC2, and ACTR3B. GALNTL5 and GALNT11 encode membrane-bound polypeptide N-acetylgalactosaminyltransferases. These enzymes catalyze O-glycosylation of peptides in the Golgi apparatus . KMT2C encodes a histone methyltransferase that can play a role in epigenetic transcriptional activation . XRCC2 encodes a protein involved in homologous recombination repair of DNA damage. Biallelic mutations in this gene have been associated with Fanconi anemia, complementation group U . ACTR3B encodes an actin-related protein that may play a role in the organization of actin cytoskeleton. It is highly expressed in brain, heart, and white blood cells .
Among these five genes, increased dosage of KMT2C and ACTR3B may be proposed to alter transcription and affect cytoskeleton, respectively, causing the pathogenicity of this triplication. However, we suggest that GALNT11 has the highest potential to be the candidate gene responsible for the observed phenotype because it was shown that the enzyme encoded by this gene can O-glycosylates NOTCH1 leading to the activation of the Notch signaling pathway . The Notch signaling pathway is a highly conserved cellular signaling system that plays a crucial role in metazoan development as it dictates cell fate through regulating differentiation, proliferation, and apoptosis, therefore influencing organ formation and morphogenesis. In mammals, the regulation of neurogenesis, myogenesis, angiogenesis, hematopoiesis, and epithelial-mesenchymal transition are all crucially influenced by Notch signaling. Defects in this pathway has been linked to a diverse group of human diseases including Alagille syndrome, Hajdu–Cheney syndrome, spondylocostal dysostoses type 1, CADASIL (cerebral arteriopathy with subcortical infarcts and leukoencephalopathy), and Alzheimer disease type 3. Notch signaling is also widely implicated in somatic genomic mutational events leading to cancer and malignancy . Therefore, increased GALNT11 dosage can potentially alter the Notch signaling pathway resulting in a widespread effects and multi-organ manifestations observed in this child with 7q36 triplication.
Although this triplication was found to be de novo and includes potential dosage-sensitive genes, it has not been previously described. Therefore, studying further cases with similar genomic rearrangements is needed before making final conclusions about the pathogenicity of this triplication. The likely mechanism for this triplication is non-allelic homologous recombination (NAHR) mediated by segmental duplications. Segmental duplications are estimated to comprise approximately 5% of the human genome and are predicted to facilitate the formation of deletions and duplications through unequal recombination between homologous regions . The region of chromosome 7 involved in this case (7q36) has been reported to be flanked by segmental duplications that could mediate the formation of chromosomal rearrangements .
In summary, we present a boy with developmental delay, growth failure, cardiovascular malformation, sensorineural hearing loss, eye manifestations, genital anomalies, lower extremity length discrepancy, bifid uvula, and distinctive facial features who was found to have an ~1.35 Mb triplication at 7q36.1q36.2. The triplicated region includes GALNTL5, GALNT11, KMT2C, XRCC2, and ACTR3B. GALNT11 encodes a membrane-bound polypeptide N-acetylgalactosaminyltransferase that can O-glycosylate NOTCH1 leading to the activation of the Notch signaling pathway. Therefore, increased GALNT11 dosage can potentially alter the Notch signaling pathway supporting the pathogenicity of 7q36 triplication.
We thank the child reported here and his family.
No funding was associated with this study.
Availability of data and materials
Microarray data is available at PreventionGenetics, LLC. Diane Allingham-Hawkins can be contacted at firstname.lastname@example.org in order to obtain the data.
MAAD collected clinical data and participated in writing the manuscript. DA-H reviewed and summarized molecular data and participated in writing the manuscript. AWE-H evaluated the child, collected clinical and molecular data, and participated in writing the manuscript. All authors have read and approved the manuscript.
Ethics approval and consent to participate
The study was approved by Al-Ain Medical District Human Research Ethics Committee (15/89-CRD 416/15). Informed consent was obtained from parents.
Consent for publication
Informed consent was obtained from parents who consented to publish the images as well as the medical information supplied in this case report.
DA-H is an employee of PreventionGenetics, LLC.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749–64.CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Alabdullatif MA, Al Dhaibani MA, Khassawneh MY, El-Hattab AW. Chromosomal microarray in a highly consanguineous population: diagnostic yield, utility of regions of homozygosity, and novel mutations. Clin Genet. 2017;91(4):616–22.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.